Ptc Therapeutics (PTCT) Stock Price, Quote & News

Company Profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spi...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 222 7000

Website: www.ptcbio.com

Address:

500 Warren Corporate Center Drive, Warren, United States

Thelonius_Stonk Jun. 4 at 5:03 PM

$PTCT thoon

1 · Reply

codename41 May. 29 at 1:50 PM

$PTCT load

0 · Reply

Ak4777 May. 28 at 2:45 PM

$PTCT 💎

0 · Reply

Thelonius_Stonk May. 27 at 7:58 PM

$PTCT the beast waking up

0 · Reply

Quantumup May. 27 at 10:40 AM

JPMorgan🏁 $LRMR and said: We are initiating coverage of Larimar Therapeutics (LRMR) with an Overweight rating and a Dec 2027 price target of $9. $PTCT SLDB BIIB DSGN $LXEO Larimar's lead asset is nomlabofusp (nomla; CTI-1601), a subcutaneously administered, recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare neurodegenerative disorder. In the near-term, in 2Q26, we expect to see topline results from the ongoing open-label (OL) study as well as feedback from the company's type B meeting with the FDA to align on the overall BLA package readiness. The company expects a rolling BLA submission for accelerated approval (AA) in June 2026, pending FDA feedback, using skin FXN levels as a surrogate endpoint, with the final submission including the CMC module expected in 2H26; if approved, nomla would be the first FXN replacement therapy for FA, with a potential U.S. approval and launch in 1H27.

0 · Reply

JasonCO May. 20 at 1:43 PM

$PTCT how the hell did I get filled at $62.83 this morning? Whatever

0 · Reply

NVDAMillionaire May. 19 at 9:54 PM

$PTCT Outstanding article that hits the mark on PTCT's current state. So if you want to refresh your PTCT insights or learn about PTCT from scratch, this is a must read. https://everyticker.com/quote/PTCT/analysis/sephience-s-blockbuster-launch-and-strategic-clarity-redefine-ptc-therapeutics-path-to-profitability-nasdaq-ptct

0 · Reply

SanKish May. 17 at 10:45 PM

$ACAD $LQDA $PTCT $XBI both of you should get on the board. Some of us have been holding because of the potential but it has been few years now. Either the company executes the growth model or sells the potential to a buyer. Thanks for sharing your detailed analysis. I am not sure though if there will be much of a change by fall as there can be a market driven downturn by then.

0 · Reply

outlawinvestor1 May. 17 at 6:51 PM

$ACAD $PTCT $XBI nice work. unbelievable value on the table for acadia imho, given the analysis below doesn't even include pipeline pys opportunity. including $LQDA as well.

1 · Reply

Night_Owl_Biotech May. 17 at 6:05 PM

Analysts project $ACAD to generate slightly more revenues than $PTCT over the next 5 & 10 years. Both ACAD & PTCT have historic gross margin profiles in the low nineties. Actual FY2025 gross margin for both was 92%. Even though analysts project ACAD to generate more revenues than PTCT at the same gross margin profile, ACAD's market cap is roughly 60% of PTCT's market cap. Because PTCT's capital structure includes meaningful term debt, PTCT's enterprise value is about 150% higher than ACAD. The attachment graphs analyst consensus of both over the next 10 years. Both had their 1st FDA approval 9 years ago. Reading the graph knowing both generate the same gross margin, does it seem logical PTCT's enterprise value is 150% higher than ACAD? We're not bashing PTCT. This is not investment advice. Rather, we're genuinely trying to understand the disconnect in valuation. $XBI $IBB $IBBQ

0 · Reply

PTC Therapeutics Transcript: AGM 2026

2026-05-27T13:16:50.000Z - 12 days ago

Market Cap	5.89B
Revenue (ttm)	1.73B
Net Income (ttm)	682.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	165.38
Profit Margin	39.44%
Debt to Equity Ratio	-14.49

Volume	1,293,281
Avg Vol	1,191,664
Day's Range	N/A - N/A
Shares Out	82.95M
Stochastic %K	55%
Beta	0.56
Analysts	Strong Sell
Price Target	$91.20